CVS Health Corp. stock (US1266501006): Analyst price targets in focus after recent gains

CVS Health Corp. shares continue to attract attention on the New York Stock Exchange as large investors adjust their positions and major U.S. banks reiterate constructive views, highlighting the stock’s role in the United States health care and pharmacy retail landscape. According to data cited by MarketBeat on 06/01/2026, CVS Health opened the new trading week around the low-90 USD area, with the stock having traded between roughly 58.50 USD and 98.43 USD over the past 12 months on the NYSE, underscoring a significant recovery from last year’s lows.

Fresh institutional activity has also been reported: MUFG Securities EMEA plc disclosed that it boosted its holding in CVS Health by 394.3% in the fourth quarter, purchasing 95,736 additional shares to reach 120,013 shares valued at about 9.5 million USD, while Nomura Asset Management Co. Ltd. trimmed its stake by 2.9% by selling 25,640 shares but still held 861,517 shares worth approximately 68.4 million USD, according to filings reported on 06/01/2026. The stock traded at 90.97 USD at the start of trading on Monday 06/01/2026 on the NYSE, underscoring its relevance for U.S.-based investors focused on S&P 500 health care names and for international investors following U.S. health care equities.

As of: 01/06/2026

By the editorial team - specialized in equity coverage.

CVS Health Corp.: core business model

CVS Health combines a nationwide U.S. pharmacy chain with pharmacy benefit management and health insurance operations, generating revenue largely from prescription volumes, insurance premiums and integrated health care services.

What banks and research houses say about CVS Health Corp.

Analyst sentiment toward CVS Health remains broadly positive, with several U.S. banks maintaining overweight or buy stances and lifting price targets as the company integrates its health services strategy. Truist raised its price target on CVS Health from 102 USD to 108 USD while keeping a buy rating, according to a note dated 06/01/2026, which also cited a mean analyst target of 100.92 USD and an average rating in the overweight range based on FactSet data. This follows earlier moves by Morgan Stanley, which increased its price objective from 93 USD to 106 USD with an overweight rating in a report referenced in early May 2026, and Piper Sandler, which reiterated an overweight rating alongside a 113 USD price target as reported by Investing.com on 05/2026.

Across the analyst community, consensus figures compiled by MarketBeat indicate that around 22 analysts rate CVS Health as a buy and four as a hold, producing an overall "Moderate Buy" consensus and an average target price close to the high-90 USD area as of the latest updates cited on 06/01/2026. These targets sit above the roughly 90 USD spot price quoted at the start of the week, reflecting expectations that the company’s scale in U.S. pharmacy operations, pharmacy benefit management and insurance could support further earnings development over time.

Conclusion

The latest trading data and institutional filings highlight how CVS Health remains a core U.S. health care stock with active participation from large international investors and a share price that has rebounded markedly from last year’s lows. At the same time, the analyst community’s mix of overweight and buy ratings, along with triple-digit U.S. dollar price targets, shows that banks continue to monitor execution on the company’s integrated pharmacy and health services strategy closely. For investors tracking U.S. health care equities, the interaction between earnings delivery, balance sheet discipline and the evolving regulatory environment in the United States will remain central variables for how the CVS Health share price develops over the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.